Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Gotham Asset Management LLC

Gotham Asset Management LLC trimmed its holdings in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 48.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,821 shares of the company's stock after selling 7,357 shares during the period. Gotham Asset Management LLC's holdings in Guardant Health were worth $239,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of GH. Guyasuta Investment Advisors Inc. purchased a new position in Guardant Health in the 4th quarter valued at about $206,000. Entropy Technologies LP purchased a new stake in shares of Guardant Health during the fourth quarter worth about $377,000. Stifel Financial Corp raised its position in shares of Guardant Health by 25.1% in the fourth quarter. Stifel Financial Corp now owns 49,927 shares of the company's stock valued at $1,525,000 after buying an additional 10,006 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Guardant Health during the fourth quarter valued at approximately $2,211,000. Finally, Swiss National Bank lifted its stake in shares of Guardant Health by 1.0% during the fourth quarter. Swiss National Bank now owns 241,900 shares of the company's stock valued at $7,390,000 after buying an additional 2,500 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Morgan Stanley upped their target price on Guardant Health from $42.00 to $52.00 and gave the company an "overweight" rating in a research note on Thursday, March 6th. Guggenheim reaffirmed a "buy" rating and set a $56.00 price objective on shares of Guardant Health in a research note on Monday, February 24th. Piper Sandler reiterated an "overweight" rating and set a $60.00 price objective (up from $50.00) on shares of Guardant Health in a report on Tuesday, May 6th. The Goldman Sachs Group boosted their target price on shares of Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a report on Friday, February 21st. Finally, Raymond James reaffirmed an "outperform" rating and set a $59.00 price target (up previously from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Twenty-one research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $52.32.

Guardant Health Stock Up 2.9%

Shares of NASDAQ GH traded up $1.11 during trading on Tuesday, reaching $39.11. 288,137 shares of the stock were exchanged, compared to its average volume of 2,137,998. The company has a market capitalization of $4.85 billion, a price-to-earnings ratio of -10.98 and a beta of 1.49. The business's 50-day moving average price is $43.22 and its 200 day moving average price is $40.31. Guardant Health, Inc. has a twelve month low of $20.14 and a twelve month high of $52.92.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $203.47 million for the quarter, compared to the consensus estimate of $189.91 million. During the same quarter in the previous year, the firm posted ($0.46) EPS. The firm's quarterly revenue was up 20.8% on a year-over-year basis. As a group, sell-side analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Insider Activity at Guardant Health

In other Guardant Health news, CEO Amirali Talasaz sold 106,784 shares of the stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the transaction, the chief executive officer now owns 2,202,672 shares of the company's stock, valued at $107,952,954.72. This trade represents a 4.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 107,132 shares of company stock valued at $5,248,393 over the last ninety days. Corporate insiders own 6.10% of the company's stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.